Morgan Stanley downgraded MorphoSys to Equal Weight from Overweight with a price target of $10.40, up from $9.20. The analyst expects European Union biopharma to offer a “safe haven” from macro and earnings growth concerns. While the firm continues to favor growth and innovation narratives in biopharma over the long term, it expects investors to reward earnings upgrade stories near term.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MOR: